Effects of probiotics on the gastrointestinal tract

被引:36
作者
Snelling, AM [1 ]
机构
[1] Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England
关键词
alternative therapeutics; gastrointestinal disease; gastrointestinal tract infection; lactobacilli; probiotics;
D O I
10.1097/01.qco.0000182103.32504.e3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review This review. summarizes recent developments in our understanding of what gastrointestinal disorders probiotics can be of benefit for, focussing on conditions associated with infection or disruption of the normal gut flora. New insights into the effects administered strains can have in the, gut their safety,and potential for future development, Will also be discussed. Recent findings Recent clinical studies have shown that probiotics can p protect young children from diarrhoeal illness, including antibiotic-associated diarrhoea. They may also protect neonates from necrotizing enterocolitis. In. adults, they can help prevent or reduce the severity of diarrhoeal illness, and ameliorate side-effects for those undergoing antibiotic therapy for infection. Researchers are looking at combining probiotics, with prebiotics to enhance anti-inflammatory effects and restore colonization resistance of the commensal flora. New technologies are elucidating complex effects on gene expression in the gut, the probiotic, and bacterial pathogens. Recombinant strains capable of binding bacterial toxins are being developed, as novel therapeutics against gastrointestinal infection. Summary Considering the clinical trial evidence of therapeutic benefit, probiotics are an treatment modality for prevention and amelioration of diarrhoeal illness. Better understanding of strain-specific effects, dosing regimens and any contraindications should help resolve this.
引用
收藏
页码:420 / 426
页数:7
相关论文
共 77 条
[71]   Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice [J].
Vandenbroucke, K ;
Hans, W ;
Van Huysse, J ;
Neirynck, S ;
Demetter, P ;
Remaut, E ;
Rottiers, P ;
Steidler, L .
GASTROENTEROLOGY, 2004, 127 (02) :502-513
[72]   Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction [J].
Verdú, EF ;
Bercík, P ;
Bergonzelli, GE ;
Huang, XX ;
Blennerhasset, P ;
Rochat, F ;
Fiaux, M ;
Mansourian, R ;
Corthésy-Theulaz, I ;
Collins, SM .
GASTROENTEROLOGY, 2004, 127 (03) :826-837
[73]  
von Wright A, 2005, CURR PHARM DESIGN, V11, P17
[74]  
Wang KY, 2004, AM J CLIN NUTR, V80, P737
[75]   NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917:: A novel effect of a probiotic bacterium [J].
Wehkamp, J ;
Harder, J ;
Wehkamp, K ;
Wehkamp-von Meissner, B ;
Schlee, M ;
Enders, C ;
Sonnenborn, U ;
Nuding, S ;
Bengmark, S ;
Fellermann, K ;
Schröder, JM ;
Stange, EF .
INFECTION AND IMMUNITY, 2004, 72 (10) :5750-5758
[76]   Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents [J].
Weizman, Z ;
Asli, G ;
Alsheikh, A .
PEDIATRICS, 2005, 115 (01) :5-9
[77]   Intestinal immunity of Escherichia coli NISSLE 1917:: a safe carrier for therapeutic molecules [J].
Westendorf, AM ;
Gunzer, F ;
Deppenmeier, S ;
Tapadar, D ;
Hunger, JK ;
Schmidt, MA ;
Buer, J ;
Bruder, D .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2005, 43 (03) :373-384